Liudmyla G Savchenko1, Nataliia I Digtiar1, Liudmyla G Selikhova1, Elvira I Kaidasheva2, Oksana A Shlykova3, Liudmyla E Vesnina3, Igor P Kaidashev1. 1. Department of Internal Medicine No.3 with Phthisiology, Ukrainian Medical Stomatological Academy, 23 Shevchenko Str.,Poltava, Ukraine. 2. Endocrinology Department, City Clinical Hospital No. 2, 7A Monastyrska Str.,Poltava, Ukraine. 3. Research Institute for Genetics and Immunological Grounds of Pathology and Pharmacogenetics, Ukrainian Medical Stomatological Academy, 23 Shevchenko Str.,Poltava, Ukraine.
Abstract
INTRODUCTION: Liraglutide (L) is the analogue of human glucagon-like peptide 1 which stimulates glucose-dependent insulin secretion and can modify the level of inflammatory biomarkers. L can influence NF-kB inflammatory cascade, but the mechanisms of anti-inflammatory activities of L remain to be determined. In animal models L influenced an activity of Sirtuin 1(SIRT1). Moreover, recent evidences strongly suggest that SIRT1 up-regulation may serve as a potent therapeutic approach against development and progression of diabetic complications. The aim of this study was to investigate L effects directed on the pro-inflammatory NF-kB pathway and expression of SIRT1 in obese patients with type 2 diabetes mellitus (DM). MATERIALS AND METHODS: 15 obese patients with type 2 diabetes were studied, all using metformin (1-2 g/day) and sulfonylurea (glimiperide). All patients received L 1.2 mg daily add-on to stable therapy for 6 weeks. Blood samples were collected before, 6 weeks after start of treatment and after an overnight fast 6 weeks after stopping L, mononuclear cells (MNC) were isolated. The mRNA expressions of TNF-α, TLR2, TLR4, NOD1, IL-2 and SIRT1 were measured in MNC by RT-PCR. Ceruloplasmin concentration was measured in plasma by photometric method. RESULTS: In this add-on pilot clinical investigation we received new data that L can inhibit proinflammatory NF-kB pathway by increased SIRT1 expression in obese patients with type 2 DM improving metabolic profile. The mRNA expression in MNC of TNF-α, IkB, TLR2, TLR4, and plasma ceruloplasmin fell after 6 weeks of L. Expressions of IL-2 and NOD-1 were stable. There was a significant increase of SIRT1 mRNA expression. The mRNA expression in MNC of TNF-α, IkB, TLR2, TLR4, NOD1, SIRT1 and ceruloplasmin concentrations did not reverse to baseline levels after 6 weeks stopping of L treatment. IL-2 expression decreased in comparison with basic level. CONCLUSIONS: L has a potent anti-inflammatory effect as do GLP-1 agonists due to inhibition of NF-kB pathways and up-regulate SIRT1 expression, down-regulating pro-inflammatory factors including cytokines (TNF-α), extra- and intracellular receptors (TLR2, TLR4), and inflammation markers such as ceruloplasmin. Long lasting effects of L can be mediated by epigenetic regulation of NF-kB pathway by SIRT-1.
INTRODUCTION: Liraglutide (L) is the analogue of humanglucagon-like peptide 1 which stimulates glucose-dependent insulin secretion and can modify the level of inflammatory biomarkers. L can influence NF-kB inflammatory cascade, but the mechanisms of anti-inflammatory activities of L remain to be determined. In animal models L influenced an activity of Sirtuin 1(SIRT1). Moreover, recent evidences strongly suggest that SIRT1 up-regulation may serve as a potent therapeutic approach against development and progression of diabetic complications. The aim of this study was to investigate L effects directed on the pro-inflammatory NF-kB pathway and expression of SIRT1 in obesepatients with type 2 diabetes mellitus (DM). MATERIALS AND METHODS: 15 obesepatients with type 2 diabetes were studied, all using metformin (1-2 g/day) and sulfonylurea (glimiperide). Allpatients received L 1.2 mg daily add-on to stable therapy for 6 weeks. Blood samples were collected before, 6 weeks after start of treatment and after an overnight fast 6 weeks after stopping L, mononuclear cells (MNC) were isolated. The mRNA expressions of TNF-α, TLR2, TLR4, NOD1, IL-2 and SIRT1 were measured in MNC by RT-PCR. Ceruloplasmin concentration was measured in plasma by photometric method. RESULTS: In this add-on pilot clinical investigation we received new data that L can inhibit proinflammatory NF-kB pathway by increased SIRT1 expression in obesepatients with type 2 DM improving metabolic profile. The mRNA expression in MNC of TNF-α, IkB, TLR2, TLR4, and plasma ceruloplasmin fell after 6 weeks of L. Expressions of IL-2 and NOD-1 were stable. There was a significant increase of SIRT1 mRNA expression. The mRNA expression in MNC of TNF-α, IkB, TLR2, TLR4, NOD1, SIRT1 and ceruloplasmin concentrations did not reverse to baseline levels after 6 weeks stopping of L treatment. IL-2 expression decreased in comparison with basic level. CONCLUSIONS:L has a potent anti-inflammatory effect as do GLP-1 agonists due to inhibition of NF-kB pathways and up-regulate SIRT1 expression, down-regulating pro-inflammatory factors including cytokines (TNF-α), extra- and intracellular receptors (TLR2, TLR4), and inflammation markers such as ceruloplasmin. Long lasting effects of L can be mediated by epigenetic regulation of NF-kB pathway by SIRT-1.
Authors: Barbara M Brooks-Worrell; Ashley H Tjaden; Sharon L Edelstein; Brenda Palomino; Kristina M Utzschneider; Silva Arslanian; Kieren J Mather; Thomas A Buchanan; Kristen J Nadeau; Karen Atkinson; Elena Barengolts; Steven E Kahn; Jerry P Palmer Journal: Front Immunol Date: 2021-04-26 Impact factor: 7.561
Authors: Luis D'Marco; Valery Morillo; José Luis Gorriz; María K Suarez; Manuel Nava; Ángel Ortega; Heliana Parra; Nelson Villasmil; Joselyn Rojas-Quintero; Valmore Bermúdez Journal: J Diabetes Res Date: 2021-11-08 Impact factor: 4.011
Authors: Bernt Johan von Scholten; Frederik Flindt Kreiner; Søren Rasmussen; Peter Rossing; Thomas Idorn Journal: Ther Adv Endocrinol Metab Date: 2022-07-19 Impact factor: 4.435
Authors: Jennifer E Nyland; Nazia T Raja-Khan; Kerstin Bettermann; Philippe A Haouzi; Douglas L Leslie; Jennifer L Kraschnewski; Leslie J Parent; Patricia Sue Grigson Journal: Diabetes Date: 2021-09-27 Impact factor: 9.461